Communiqués Cynata Therapeutics Limited OTC Markets

Actions

CYYNF

AU000000CYP7

Recherche biotechnologique et médicale

Temps Différé OTC Markets 19:28:16 25/09/2026			Varia. 5j.	Varia. 1 janv.
0,001400 ^USD	-83,72 %		-83,72 %	-99,07 %

31/08	Cynata Therapeutics Limited publie ses résultats pour l'exercice clos le 30 juin 2026	CI
06/07	Cynata Therapeutics Limited met fin à son essai de phase 2 sur la maladie du greffon contre l'hôte et suspend ses activités externalisées	CI

Communiqués

24/10/24	Cynata Therapeutics : Alliance for Regenerative Medicine - Meeting on the Mesa	PU
08/10/24	Cynata Therapeutics : 2024 Alliance for Regenerative Medicine Meeting on the Mesa Presentation	PU
12/05/23	Cynata Therapeutics : 23 April 2023 Capital Raising Presentation	PU
07/03/22	Cynata Therapeutics : Updated Investor Presentation	PU
16/11/21	Cynata Therapeutics : AGM Presentations	PU
30/06/21	Ethics Approval for Cynata’s Clinical Trial in Diabetic Foot Ulcers	GL
03/06/21	Cynata Therapeutics : signs Licence Agreement with TekCyte to advance Clinical Trial in Diabetic Foot Ulcers	AQ
24/05/21	Cynata Therapeutics : First Patient Enrolled in Cynata’s MEND Clinical Trial	AQ
29/03/21	Cynata Therapeutics : Expands MEND clinical trial in COVID-19 and Respiratory Failure	AQ
02/03/21	Cynata Therapeutics : New Preclinical Study to Investigate the High Potency of Cymerus™ MSCs	AQ
01/03/21	Cynata Therapeutics : Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte	AQ
11/12/20	Cynata Therapeutics : Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline	AQ
11/11/20	Cynata Therapeutics : Phase 3 Osteoarthritis Clinical Trial Commences	AQ
08/09/20	Cynata Therapeutics : Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study	AQ
17/04/20	Cynata Therapeutics : Preclinical Study Showing Beneficial Effects of Cymerus™ MSCs in Acute Respiratory Distress Syndrome Accepted for Publication in Leading Peer-Reviewed Journal	AQ
14/01/20	Cynata Therapeutics : UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia	AQ
24/11/19	Cynata Therapeutics : CYP Files Application to Commence Phase 2 CLI Clinical Trial	PU
18/12/18	Cynata Completes Clinical Study Report for Phase 1 Trial of CYP-001 in GvHD	GL
13/12/18	NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus™ MSCs in Patients with Osteoarthritis	GL
01/11/18	Cynata Therapeutics : 18.11.01.Cynata Outlook and Investor Presentation	PU
26/10/18	Cynata Therapeutics : 18.10.26.Appendix 3Y-Dr Paul Wotton	PU
23/10/18	Cynata Therapeutics : 18.10.23.September 2018 Quarterly Report	PU
18/10/18	Engineered Cymerus™ MSCs Demonstrate Anti-Cancer Effects in Preclinical Studies	GL
18/10/18	Cynata Therapeutics : 18.10.18.MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical Studies	PU
27/09/18	Cynata Therapeutics : 18.09.27.Notification of 2018 Annual General Meeting Date	PU